<DOC>
	<DOCNO>NCT00002832</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may effective treatment leukemia , myelodysplastic syndrome , chronic myelogenous leukemia relapse follow bone marrow transplantation . PURPOSE : Phase I/II trial study effectiveness decitabine peripheral stem cell transplantation treat patient leukemia , myelodysplastic syndrome , chronic myelogenous leukemia relapse bone marrow transplantation .</brief_summary>
	<brief_title>Decitabine Peripheral Stem Cell Transplantation Treating Patients Who Have Relapsed Following Bone Marrow Transplantation Leukemia , Myelodysplastic Syndrome , Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose decitabine patient relapse post allogenic bone marrow transplant . II . Determine toxicity decitabine combine filgrastim ( G-CSF ) prim allogeneic peripheral blood stem cell patient relapse within 1 year allogeneic bone marrow transplantation . III . Determine effectiveness reinducing remission patient . OUTLINE : Patients receive decitabine IV 6 hour every 12 hr 5 day . Peripheral blood stem cell ( PBSC ) administer 5 day last dose decitabine . Donors receive filgrastim subcutaneously ( SQ ) daily every 12 hour start 2-4 day prior first PBSC collection . If insufficient number cell collect , bone marrow harvest supplementation . Donor cell collect prior decitabine infusion . Patients receive filgrastim SQ administer daily start 1 day PBSC infusion blood count recover . For GVHD prophylaxis , patient receive cyclosporine IV daily day -2 , orally dose tolerable . Dose decitabine escalate cohort 3-6 patient . If dose limit toxicity occur 2 6 patient give dose level , dose declare maximum tolerated dose . Patients follow weekly . If none first 5 patient survive remission 100 day , study terminate . PROJECTED ACCRUAL : At least 15 patient accrue study 2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute leukemia , myelodysplastic syndrome chronic myelogenous leukemia ( CML ) accelerate phase blast crisis relapse within 1 year allogeneic bone marrow transplantation Must candidate second course high dose chemoradiotherapy PATIENT CHARACTERISTICS : Age : 60 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 3 mg/dL Renal : Creatinine le 2 mg/dL Cardiovascular : Greater 40 % ejection fraction per MUGA scan ECHO Other : Not pregnant No serious intercurrent illness No active CNS disease Must ineligible protocol high priority No active acute graft v host disease ( GVHD ) great grade 2 extensive chronic GVHD No active uncontrolled infection Original marrow donor must undergo filgrastim prim peripheral blood stem cell collection PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Sandimmune</keyword>
	<keyword>CYA</keyword>
	<keyword>Cyclosporin A</keyword>
	<keyword>Peripheral blood stem cell</keyword>
	<keyword>PBSC</keyword>
	<keyword>Allogeneic bone marrow transplantation</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>